Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells (Q35558610)

8 August 2017

title

Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells (English)

1 reference

8 August 2017

0 references

Stine Hole

1

1 reference

8 August 2017

Astrid M Pedersen

series ordinal

2

1 reference

8 August 2017

Anne E Lykkesfeldt

series ordinal

3

1 reference

8 August 2017

Christina W Yde

series ordinal

4

1 reference

8 August 2017

language of work or name

English

0 references

publication date

10 February 2015

1 reference

Breast Cancer Research and Treatment

8 August 2017

published in

1 reference

8 August 2017

volume

149

1 reference

8 August 2017

issue

3

1 reference

8 August 2017

page(s)

715-726

1 reference

describes a project that uses

8 August 2017

0 references

0 references

0 references

0 references

Aromatase, aromatase inhibitors, and breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

Structural basis for androgen specificity and oestrogen synthesis in human aromatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

Aurora kinase inhibitors--rising stars in cancer therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

The regulatory beta-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

A small C-terminal sequence of Aurora B is responsible for localization and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3284-8

10.1007/S10549-015-3284-8

21 January 2018

Identifiers

DOI

1 reference

8 August 2017

1 reference